Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.26% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-06-30 was 4.26%, a 12.11% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.62%, a 10.17% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-09-30 was 3.81%, a 4.96% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-06-30 was 3.80%, a 11.63% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.69%, a 1.65% increase from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.63%, a 3.71% increase from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.50%, a 118.75% increase from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.60%, a 1500.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.26% 10-Q · filed 2026-08-05 | 3.62% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 3.62% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 3.69% 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 3.81% 10-Q · filed 2025-11-05 | 3.81% 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 3.80% 10-Q · filed 2026-08-05 | 3.80% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.03% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 3.63% 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 3.63% 10-Q · filed 2025-11-05 | 3.63% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-07 | 3.90% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 3.93% 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 3.50% 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 4.10% 10-Q · filed 2024-11-06 | 3.50% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 3.50% 10-Q · filed 2024-08-13 | 3.50% 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 3.55% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 1.60% 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 2.70% 10-Q · filed 2023-11-08 | 1.60% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 2.80% 10-Q · filed 2023-08-09 | 1.60% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 1.60% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.10% 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 0.90% 10-Q · filed 2021-11-10 | 0.10% 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 0.10% 10-Q · filed 2022-08-10 | 0.10% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 0.70% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.10% 10-K · filed 2022-03-15 | |||
| 2020-09-30 | 0.10% 10-Q · filed 2021-11-10 | 0.10% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 1.68% 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |